4 results on '"Ramy Yim"'
Search Results
2. 1662. Impact of a Documented Penicillin Allergy on Antibiotic Selection in Patients with Osteomyelitis
- Author
-
Caitlin Naureckas Li, Katherine Herman, Ramy Yim, Mari M Nakamura, Esther Chu, Jayme Wilder, Maria Alfieri, Benjamin Ethier, and Brittany Esty
- Subjects
Infectious Diseases ,Oncology - Abstract
Background Penicillin allergy is the most commonly reported drug allergy, affecting approximately 10% of patients. Although historically there has been concern about administering cephalosporins to patients allergic to penicillin, the rates of cross-reactivity are only approximately 2%. As cephalosporins are the first-line and safest treatment for many infections, unnecessary avoidance of cephalosporins places patients at risk of poor disease outcomes and antibiotic-associated harms. We assessed the relationship between penicillin allergy label and antibiotic selection in pediatric patients with acute osteomyelitis. Methods We performed a retrospective review of inpatients at our quaternary children’s hospital diagnosed with osteomyelitis between 2011 and 2021. During this period, the institutional osteomyelitis clinical pathway recommended clindamycin for patients with cephalosporin but not penicillin allergy. We compared rates of antibiotics used as definitive therapy between patients with and without documented penicillin allergy. Results Of 365 patients hospitalized with a diagnosis of osteomyelitis, 41 (11.2%) had a documented penicillin allergy. First-generation cephalosporins were administered less frequently to penicillin-allergic patients compared with those without documented penicillin allergy (37% vs. 58%, p=.009), while clindamycin was administered more frequently (22% vs. 10%, p=.02). There was no significant difference in vancomycin use (2% vs. 9%, p=.17). Conclusion Patients with osteomyelitis and a penicillin allergy label were significantly less likely to receive a first-generation cephalosporin and significantly more likely to receive clindamycin. Given higher regional resistance rates and more frequent adverse effects, including Clostridioides difficile infection, of clindamycin relative to first-generation cephalosporins, these data support the need for quality improvement work to increase cephalosporin use in patients with penicillin allergy labels. Disclosures Mari M. Nakamura, MD, MPH, Gilead: Grant/Research Support.
- Published
- 2022
3. 1126. Short-Course Therapy and Transition to Enteral Antibiotics for Uncomplicated Bacteremia Due to Enterobacterales Species
- Author
-
Hanna Wardell, Ana M Vaughan-Malloy, Courtney Gidengil, Jorge J Velarde, Zana Khoury, Ramy Yim, Sarah Jones, Mari M Nakamura, and Gabriella S Lamb
- Subjects
Infectious Diseases ,Oncology - Abstract
Background Gram-negative bacteremia historically has been treated with 10-14 days of parenteral antibiotics. However, data supporting this practice are lacking, and recent evidence shows equivalent outcomes for short-course (SC) therapy (7 days) and early (by day 5) conversion to highly bioavailable enteral (PO) antibiotics for Enterobacterales bacteremia. Methods Under a QI framework, we used PDSA cycles to reduce treatment duration and increase use of PO levofloxacin or trimethoprim-sulfamethoxazole for uncomplicated Enterobacterales bacteremia among Infectious Diseases (ID) clinicians at a children’s hospital in Boston, MA. We conducted an education session on evidence to support these practices for ID faculty and fellows in October 2020. In December 2020, we implemented standardized recommendations for a 7-day duration and early PO transition for eligible patients (≥ 3-months-old, ≤ 2 days monomicrobial bacteremia, with source control and return to baseline clinical status) that could be inserted automatically into electronic consult notes. In February 2021, we reinforced this practice to ID providers. We collected data before and after these interventions on ID recommendations and on patients’ actual antibiotic management. Results From 11/01/20 to 05/31/21, mean recommended treatment decreased from 10.6 to 9.5 days; however, mean duration received was similar (11.2 vs 11.7 days) (Figure 1). The percentage of patients for whom ID recommended PO conversion and in whom transition to PO agents by day 5 occurred increased from 27% to 37.5%. Figure 1. Change in average duration of antibiotics recommended and received, in days Conclusion Education and creation of automated standardized recommendations led to decreased recommended treatment durations and increased PO conversions for Enterobacterales bacteremia, but only modestly. This quality improvement initiative demonstrates the potential benefits of education and electronic documentation tools to facilitate evidence-based practice changes, but also highlights the difficulty in changing practice even amongst ID clinicians. Further PDSA cycles will be targeted at increasing more consistent awareness among a large ID division in addition to other stakeholders. Disclosures Gabriella S. Lamb, MD, MPH, Nothing to disclose
- Published
- 2021
4. 1125. Decreasing Concomitant Vancomycin and Piperacillin-Tazobactam Use in Children to Reduce Incidence of Acute Kidney Injury
- Author
-
Gabriella S Lamb, Avram Traum, Zana Khoury, Ramy Yim, Sarah Jones, and Mari M Nakamura
- Subjects
Infectious Diseases ,Oncology - Abstract
Background Concomitant use of vancomycin (V) and piperacillin-tazobactam (PT) is associated with increased incidence of acute kidney injury (AKI). AKI develops 3 times faster on this combination compared to alternative vancomycin combinations. We sought to reduce AKI in our patients by reducing concomitant use of V/PT using a QI framework. Methods We implemented several PDSA cycles to reduce concomitant V/PT use at a 415-bed quaternary children’s hospital in Boston, MA. Interventions included substitution of PT with other agents in surgical prophylaxis guidelines and order sets starting in February 2020 and in the hospital-wide sepsis order set in March 2021. The Antimicrobial Stewardship Program reinforced these changes during daily audit-and-feedback reviews. In November 2020, we implemented an electronic alert that apprises clinicians of the AKI risk when V/PT are ordered and recommends an alternative regimen. We measured the monthly number of patients on combination V/PT, new exposures to nephrotoxic medications, AKI events, and the percentage of days with serum creatinine monitoring for patients on ≥2 nephrotoxic medications. Results From 02/01/20 to 05/31/21, the number of patients exposed to combination V/PT decreased from 23 to 6 per month (Figure 1). New nephrotoxic medication exposures declined from 17.1 to 7.7 per 1,000 patient days, and AKI events dropped from 2.8 to 0.6 per 1,000 patient days (Figures 2 and 3). The percentage of days with serum creatinine monitoring increased from 60% to 66%. Rate of New Exposures to Nephrotoxic Medications per 1000 Patient Days Conclusion Revising guidelines and electronic order sets and implementing an order alert led to marked decreases in exposures to V/PT and nephrotoxic medications overall and was associated with reduced AKI events. Use of electronic health record tools is an effective way to drive safer antimicrobial use. Disclosures Gabriella S. Lamb, MD, MPH, Nothing to disclose
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.